ATE239486T1 - Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren - Google Patents

Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren

Info

Publication number
ATE239486T1
ATE239486T1 AT96943821T AT96943821T ATE239486T1 AT E239486 T1 ATE239486 T1 AT E239486T1 AT 96943821 T AT96943821 T AT 96943821T AT 96943821 T AT96943821 T AT 96943821T AT E239486 T1 ATE239486 T1 AT E239486T1
Authority
AT
Austria
Prior art keywords
cryptosporidiosis
lactobacillus reuteri
mammals
inhibit
cryptosporidium parvum
Prior art date
Application number
AT96943821T
Other languages
English (en)
Inventor
Keith Allen Garleb
Bryan Allen Wolf
Ivan A Casas
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Application granted granted Critical
Publication of ATE239486T1 publication Critical patent/ATE239486T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT96943821T 1995-12-21 1996-12-20 Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren ATE239486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57627495A 1995-12-21 1995-12-21
PCT/US1996/020348 WO1997022353A1 (en) 1995-12-21 1996-12-20 Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals

Publications (1)

Publication Number Publication Date
ATE239486T1 true ATE239486T1 (de) 2003-05-15

Family

ID=24303696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943821T ATE239486T1 (de) 1995-12-21 1996-12-20 Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren

Country Status (9)

Country Link
US (1) US6103227A (de)
EP (1) EP0814822B1 (de)
AT (1) ATE239486T1 (de)
AU (1) AU718040B2 (de)
CA (1) CA2213434C (de)
DE (1) DE69627994D1 (de)
ES (1) ES2199305T3 (de)
NZ (1) NZ325131A (de)
WO (1) WO1997022353A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20050123583A1 (en) * 2000-12-18 2005-06-09 Hsing-Wen Sung Medical use of reuterin
ES2329020T3 (es) * 2002-10-18 2009-11-20 Biogaia Ab Procedimiento para potenciar la funcion inmunitaria en mamiferos usando cepas de lactobacillus reuteri.
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US7384628B2 (en) * 2003-06-23 2008-06-10 Agtech Products, Inc. Lactic acid bacteria and its use in direct-fed microbials
US20060078546A1 (en) * 2004-10-07 2006-04-13 Anders Zachrisson Use of lactic acid bacteria to reduce sick time
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
FI121952B (fi) 2009-05-06 2011-06-30 Oriola Oy Menetelmä pisaroina annosteltavan terveystuotteen valmistamiseksi
BR112014024159A2 (pt) 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
CA2904389C (en) 2013-03-14 2018-09-18 Jerome J. Schentag Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN107106629B (zh) * 2014-05-05 2021-01-12 G·莫格纳 通过双重免疫生物刺激来治疗肿瘤、获得性免疫缺陷综合征和白血病的疗法
KR20160144501A (ko) * 2014-05-05 2016-12-16 지오바니 모그나 L. 류테리 ler03 및/또는 l. 살리바리우스 ls06을 포함하는 항-종양 화학요법, 백혈병 치료 또는 보조 요법을 받는 개체에서 바이러스 또는 박테리아 감염을 치료하거나 예방하는데 사용하기 위한 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
US5800813A (en) * 1996-11-12 1998-09-01 Biogaia Biologics Ab Treatment of cryptosporidium infections

Also Published As

Publication number Publication date
NZ325131A (en) 2000-08-25
AU1295897A (en) 1997-07-14
CA2213434A1 (en) 1997-06-26
EP0814822A1 (de) 1998-01-07
US6103227A (en) 2000-08-15
DE69627994D1 (de) 2003-06-12
WO1997022353A1 (en) 1997-06-26
CA2213434C (en) 2008-12-09
ES2199305T3 (es) 2004-02-16
AU718040B2 (en) 2000-04-06
EP0814822B1 (de) 2003-05-07

Similar Documents

Publication Publication Date Title
ATE239486T1 (de) Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren
Knauth The design of shift systems
HUP9901250A2 (hu) Elválasztó eszközzel ellátott abszorbens cikkek
DK0508701T3 (da) Probiotikum
NO974558D0 (no) Cerealt matprodukt med höyt innhold av opplöselig fiber
EP1119362A4 (de) Verwendungsmethode von tetracyclinverbindungen zur steigerung der interleukin-10 produktion
France et al. Risk for high blood pressure and decreased pain perception
IT1224733B (it) Trattamento batterico di conservazione della qualita' del fieno tramite aggiunta di microorganismi del genere bacillus
NO883614D0 (no) Molekylaer kloning og ekspresjon av humant il-3.
Aoki et al. Increased response of blood pressure to rest and handgrip in subjects with essential hypertension
ATE333281T1 (de) Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
ES2147308T3 (es) Metodo para diagnosticar los trastornos inflamatorios del intestino.
Altman Diurnal activity rhythm of rats with lesions of superior colliculus and visual cortex
ES2066847T3 (es) Diagnostico y tratamiento del sindrome de fatiga cronica.
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
TR200401952T4 (tr) Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı
de Visser et al. Amyotrophy of the hands and pyramidal features of predominantly the legs segregating within one large family
Bruce Ventricular tachycardia following exercise in a case of angina pectoris
TR199801799T2 (xx) A��r� sald�rganl�k tedavisi.
Oh et al. Double anastomosis of median-ulnar and ulnar-median nerves
Rickman et al. The isolation of T. brucei-like organisms from man
Harris et al. The Role of Peripheral Neuromuscular Elements in the Tremor-Related Symptoms of the High Pressure Nervous Syndrome
James Clinical lecture on two cases of malarial Neuritis with tremors
Berti Dentro il Castelnuovo di Padova
Scruggs et al. Why does thumb position affect the median thenar compound muscle action potential?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties